Envista Holdings Corporation research snapshot
NVST AI stock analysis currently reads Envista Holdings as a global dental products company with strong free cash flow generation and a net cash balance sheet, but with depressed GAAP earnings from restructuring and impairment charges. At the July 10, 2026 data cutoff, NVST traded near $25.91 with a verified market capitalization near $4.22 billion. The forward P/E near 20x and P/FCF near 19.5x suggest the market is pricing in a gradual earnings recovery. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$25.91
Market cap
$4.22 billion
AI score
58 / 100
Rating
Turnaround dental platform, cash flow supports valuation
Trend status
Recovering from 52-week low with improving volume trend
Data cutoff (updated weekly)
July 10, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Envista sells dental implants, orthodontic systems, imaging equipment, and consumables to dentists and labs globally. Recurring consumables and services provide revenue stability, but equipment and Spark aligner growth are more discretionary. | Medium |
| Moat | Moat comes from installed equipment base, consumables pull-through, brand recognition (Nobel Biocare, Ormco, Kerr), and digital workflow integration. Competition from Straumann, Align Technology, and Dentsply Sirona limits pricing power. | Medium |
| Management | Management has focused on restructuring, Spark clear aligner profitability, and debt reduction since the 2024 CEO transition. Capital allocation includes buybacks and targeted M&A, but execution track record is still being established. | Medium-low |
| Financial trend | TTM revenue near $2.81 billion with modest growth. GAAP net income depressed at $67.7 million due to non-cash charges, but levered free cash flow of $216 million provides real earnings power. Net cash position of roughly $270 million. | Medium-high |
| Valuation | TTM P/E of 63x is misleading due to low GAAP earnings. Forward P/E near 20x and EV/EBITDA near 12x are more reasonable. P/FCF near 19.5x with FCF yield above 5% suggests value territory if earnings normalize. | Medium |
| Technical trend | NVST has recovered from its 52-week low of $18.77 and trades above its 50-day and 200-day moving averages. Momentum indicators show improving volume but the stock remains below the 52-week high of $30.42. | Medium-high |
| Risk level | Key risks are competitive pressure from Align Technology and Straumann, consumer spending sensitivity on elective dental procedures, China macro exposure, raw material cost inflation, and potential further restructuring charges. | Medium-high |
| AI confidence | High confidence for the business model, balance sheet, cash flow, and market comparables. Lower confidence for precise earnings timing and competitive dynamics in clear aligners. | High data confidence, medium forecast confidence |
NVST AI stock forecast
NVST stock forecast scenarios are built around earnings normalization. The bull case depends on Spark clear aligner profitability, procedure volume recovery, and margin expansion from restructuring. The bear case centers on market share loss and continued GAAP earnings drag.
$30 - $38
Consistent EPS growth above 20% annually driven by Spark clear aligner share gains, China procedure recovery, restructuring benefits exceeding targets, and successful new product launches. Dental industry volume growth returns to trend.
$22 - $30
Modest EPS recovery of 10-15% annually as restructuring benefits flow through. Spark clear aligners maintain but do not gain significant share. Dental procedure volumes grow at trend. Normalized P/E in the 18-22x range is maintained.
$14 - $22
Market share loss in implants and orthodontics to larger competitors. Spark clear aligner profitability disappoints. China volumes remain weak. Additional impairment charges or leverage increases from debt-financed acquisitions.
NVST AI technical analysis
NVST AI technical analysis shows the stock in an intermediate recovery phase after establishing a base near $18.77. The stock trades above key moving averages but faces resistance at the 52-week high. Volume trends suggest gradual accumulation.
| Level | Value | Why it matters |
|---|---|---|
| Support 1 | $23.00 | 50-day moving average near this level. A break below could signal a retest of prior support. |
| Support 2 | $20.50 | 200-day moving average area. Previous consolidation zone before the recent rally. |
| Resistance 1 | $28.00 | Pre-breakdown level from late 2025. First major overhead supply zone. |
| Resistance 2 | $30.42 | 52-week high. A break above this level would signal a new uptrend leg. |
| 50-day MA | ~$23.20 | Stock is trading above this level, indicating short-term bullish momentum. |
| 200-day MA | ~$20.40 | Well above this level, confirming the medium-term trend has turned positive. |
| Volume trend | Improving | Average daily volume near 3.1 million shares with above-average volume on up days. |
| RSI (14) | ~58 | Neutral zone with room to run in either direction. Not overbought or oversold. |
| Invalidation level | $18.77 | A break below the 52-week low would invalidate the recovery thesis and suggest a new downtrend. |
NVST AI trading strategy
NVST AI trading strategy framework considers the stock as a potential mean-reversion and trend-following setup within a recovering dental sector. The strategies below are analytical frameworks, not personalized trading advice.
Enter on pullbacks to the 50-day moving average near $23 with rising volume. Use the $28 resistance level as the first take-profit target and the $30.42 52-week high as the extended target. Trail stops below the 50-day MA as the trend develops.
Risk 5-7% per trade. Invalidate the setup if price closes below $20.50 (200-day MA) on above-average volume.
Look for oversold RSI readings (below 35) during earnings-related weakness. Buy near the $22-23 support zone. Target a return to the $26-28 range over 4-8 weeks. Use a 2:1 reward-to-risk ratio as a minimum entry filter.
Position size at 60% of normal. Invalidate on a close below $20 with high volume, which would suggest a structural rather than cyclical decline.
NVST has shown significant post-earnings moves. Consider holding through earnings only if positioned near support levels. The implied move from options can be compared to the actual historical average move of roughly 5-7%.
Reduce position size by 50% before earnings. Use option strategies (credit spreads) instead of outright longs to define risk.
Investment research summary
Envista sells dental products and digital workflow solutions to dental professionals. Customers pay for reliable instruments, consumables, and software that improve clinical outcomes and practice efficiency. Recurring consumables and services revenue provides base stability.
The moat is moderate and relies on installed equipment, consumables pull-through, brand heritage (Nobel Biocare in implants, Ormco in orthodontics), and DTX Studio digital workflow integration. The moat is not widening as competitors invest aggressively in clear aligners, CBCT imaging, and chairside workflows.
The thesis fails if Spark clear aligners cannot achieve sustainable profitability against Invisalign, if Straumann takes additional implant share, if China volumes remain structurally lower, or if restructuring savings are offset by competitive price pressure.
Post-spin management has prioritized debt reduction, Spark profitability, and restructuring. Share buybacks in 2025-2026 signal confidence. Key-person risk exists given recent CEO transition. Capital allocation track record is still being built under the current leadership.
Dental is a steady-growth industry driven by aging demographics, cosmetic dentistry demand, and digital workflow adoption. Clear aligners and guided implant surgery are secular growth areas. However, the industry is cyclical with consumer spending and dental insurance coverage.
At $25.91, NVST trades at 19.5x levered free cash flow and an EV/EBITDA of 12.2x. Forward P/E of 20x assumes normalized earnings. The balance sheet is net cash. The margin of safety depends on whether earnings normalize in 1-2 years or if competitive pressures delay the recovery.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $25.91 | Yahoo Finance | July 10, 2026 |
| Market cap | $4.22 billion | Yahoo Finance | July 10, 2026 |
| Shares outstanding | ~162.7 million | Yahoo Finance / SEC filings | July 10, 2026 |
| Enterprise value | $4.72 billion | Yahoo Finance | July 10, 2026 |
| TTM revenue | $2.81 billion | Yahoo Finance | July 10, 2026 |
| TTM net income | $67.7 million | Yahoo Finance | July 10, 2026 |
| TTM levered FCF | $216.3 million | Yahoo Finance | July 10, 2026 |
| Cash and equivalents | $1.08 billion | Yahoo Finance | July 10, 2026 |
| P/E (TTM) | 63.2x | Yahoo Finance / Verified | July 10, 2026 |
| Forward P/E | ~20.3x | Yahoo Finance | July 10, 2026 |
| EV/EBITDA | 12.2x | Yahoo Finance | July 10, 2026 |
| P/FCF (TTM) | 19.5x | Verified calculation | July 10, 2026 |
| 52-week range | $18.77 - $30.42 | Yahoo Finance | July 10, 2026 |
| Beta (5Y) | 0.86 | Yahoo Finance | July 10, 2026 |
This NVST AI stock analysis page is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All forecast scenarios are based on publicly available data and analytical assumptions that may prove incorrect. Past performance is not indicative of future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Data cutoff: July 10, 2026. Prices and metrics may have changed since this date.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
